Raffles Medical Group: Strong track record; still a BUY (DBSV)

Expect good track record to continue. Raffles Medical Group (RMG) has delivered consistent core earnings growth over the years, even amidst turbulent times. Its strong track record makes it a good stock to own as we enter into 2012, given the global macroeconomic uncertainties. From FY06 to FY10, RMG's revenue and core earnings expanded at a healthy CAGR of 15.5% and 28.1%, respectively. We forecast its core earnings to increase at 15.0% for FY11 and a further 19.5% in FY12. This would be driven by continued patient load growth, higher revenue intensity per patient, expansion of specialist services (especially sub-specialties) and further traction gains from its Shanghai medical centre (currently still loss-making).

Defensive earnings provide stability. We see limited risks from RMG's defensive earnings, although the group is not entirely immune to a macroeconomic slowdown as some patients might practice restraint over their discretionary spending. This would come in the form of postponing elective surgeries and/or seeking cheaper alternatives in the public sector or regional competitors.

Healthy industry fundamentals. We remain sanguine on the prospects of Singapore's healthcare sector. Growth is expected to be fuelled by demographic changes and rising affluence in the region, resulting in higher medical tourism dollars. Although RMG's new Specialist Medical Centre in the Orchard area would come on stream in 1H13 and its hospital expansion (additional 102,408 sf) estimated to be ready only by FY14, this would be partially mitigated by the creation of ~15,000 sf of new medical space at its existing hospital in 1H12. This involves the relocation of its back office operations, thus allowing the group to open new specialist clinics to cater to rising demand for higher quality private healthcare services.

But competitive landscape is intensifying. The targeted opening of Parkway Novena Hospital in Jul 2012 and Singapore HealthPartners' Connexion in 2013 would undoubtedly create additional competitive pressures for RMG. But we believe that these developments could raise the reputation of Singapore's medical hub status and attract more foreign patients and other health services here.

Quality healthcare play. Current valuations for RMG do not appear demanding, in our view, with the stock trading at 19.9x FY12F PER. While this is comparable to its peers' average of 19.7x, RMG commands significantly stronger margins and ROE. Maintain BUY with an unchanged fair value estimate of S$2.61, based on 24x FY12F EPS.